Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.

Poullenot, Florian; Bioulac-Sage, Paulette; Laumonier, Hervé; Saric, Jean; Carteret, Thibault; Blanc, Jean-Frédéric

Poullenot, Florian; Bioulac-Sage, Paulette; Laumonier, Hervé; Saric, Jean; Carteret, Thibault; Blanc, Jean-Frédéric.

Affiliation

Poullenot F; Department of Gastroenterology and Hepatology, Saint-André Hospital, University Hospital of Bordeaux and Victor Segalen University , Bordeaux , France.

Acta Oncol ; 53(3): 420-3, 2014 Mar.

Article in En | MEDLINE | ID: mdl-23713857

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/drug therapy; Niacinamide/analogs & derivatives; Phenylurea Compounds/therapeutic use; Aged; Antineoplastic Agents/adverse effects; Carcinoma, Hepatocellular/diagnostic imaging; Carcinoma, Hepatocellular/surgery; Dose-Response Relationship, Drug; Humans; Liver Neoplasms/diagnostic imaging; Liver Neoplasms/surgery; Male; Middle Aged; Niacinamide/adverse effects; Niacinamide/therapeutic use; Phenylurea Compounds/adverse effects; Radiography; Sorafenib; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Niacinamide / Carcinoma, Hepatocellular / Liver Neoplasms / Antineoplastic Agents Type of study: Diagnostic_studies Limits: Aged / Humans / Male / Middle aged Language: En Journal: Acta Oncol Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: France Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google